Influência do tempo de evolução prévio ao diagnóstico inicial incapacidades presentes no exame inicial de pacientes portadores de hanseníase multibacilar

Maria Inês Fenandes Pimentel; José Augusto da Costa Nery; Esther Borges; Rosângela Rolo Gonçalves; Euzenir Nunes Samo

doi:10.47878/hi.2002.v27.36415

Authors

Maria Inês Fenandes Pimentel Doutora em Dermatologia pela Universidade Federal do Rio de Janeiro; Professora Titular de Dermatologia na Escola de Ciências Médicas da Uni-FOA, Volta Redonda, RJ.
José Augusto da Costa Nery Mestre em Dermatologia pela Universidade Federal Fluminense, Doutor em Doenças Infecciosas e Parasitárias pela Universidade Federal do Rio de Janeiro; médico da Fundação Oswaldo Cruz, Rio de Janeiro, RJ.
Esther Borges Fisioterapeuta da Fundação Oswaldo Cruz, Rio de Janeiro, RJ.
Rosângela Rolo Gonçalves Terapeuta ocupacional da Fundação Oswaldo Cruz, Rio de Janeiro, RJ.
Euzenir Nunes Samo Vice-Presidente de Pesquisa da Fundação Oswaldo Cruz, Rio de Janeiro, RJ.

DOI:

https://doi.org/10.47878/hi.2002.v27.36415

Keywords:

Multibacillary leprosy, disability grade, delay in diagnosis

Abstract

Aiming to determine the influence of the evolution period prior to diagnosis in the prevalence of disabilities detected at the initial examination of multibaci lary leprosy patients, one hundred patients (18% BB; 47% BL; and 35% LL) were asked in anamnesis to ascertain the evolution period of the disease before the diagnosis was made. More than 2/3 of the patients (71%) had diagnosis in a time period of over 6 months of disease evolution (55% in a time period of over 12 months of disease evolution). The patients were evaluated in respect to physical disabilities at the time of diagnosis through the disability grade before treatment (DGBT). In relation to the disabilities presented at the initial examination, 44% presented DGBT = 0; 33% presented DGBT = 1; 22% presented DGBT = 2; and 1% presented DGBT = 3. The evolution period prior to diagnosis was correlated with DGBT (correlation coefiáent = 0.243440135), and the Kruskal-Wallis one way analisys of variance demonstrated p value = 0.012606. It was statistically significant even when the evolution time prior to diagnosis was grouped in 12-months periods (p = 0.019428) and in up to 6 months and above 6 months of disease (p = 0.012613). Patients with longer evolution periods before diagnosis presented higher disability grade before treatment, while patients whose diagnosis was made up to 6 months of disease, presented less disabilities. These data show the importance of early diagnosis in the prevention of disabilities related to leprosy.

Downloads

Download data is not yet available.

References

1 BEKRI W, GEBRE S., MENGISTE A., SAUNDERSON P. R. e ZEWGE S. Delay in presentation and start of treatment in leprosy patients: a case-control study of disabled and non-disabled patients in three different settings in Ethiopia. Int J Lepr 1998, 66 (1): 1-9.
2 CHEN X. S., LI W. Z., JIANG C. e YE G. Y. Leprosy in China: delay in the detection of cases. Ann Trop Med Parasitol 2000, 94 (2): 181-188.
3 CROFT R. P., RICHARDUS J. H., NICHOLLS P. G. e SMITH W. C. Nerve function impairment in leprosy: design, methodology and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh ( The Bangladesh Acute Nerve Damage Study). Lepr Rev 1999, 70 (2): 140 —159.
4 GUIA DE CONTROLE DA HANSENÍASE / Ministério da Saúde. Fundação Nacional de Saúde. Centro Nacional de Epidemiologia. Coordenação Nacional de Dermatologia Sanitária. Segunda edição, Brasilia, 1994, 156 p.
5 JOB C. K. Nerve damage in leprosy. Int J Lepr 1989, 57 (2): 532-539.
6 LOCKWOOD D. N. e REID A. J. The diagnosis of leprosy is delayed in the United Kingdom. Q J M 2001, 94 (4): 207-212.
7 MEIMA A., SAUNDERSON P. R., GEBRE S., DESTA K., VAN OORTMARSSEN G. J. e HABBEMA J. D. Factors associated with impairments in new leprosy patients: the AMFES cohort. Lepr Rev 1999, 70 (2): 189-203.
8 MEKLAFI G. A e AL-QUBATI Y. Retrospective analysis of 194 leprosy cases in Republic of Yemen. Indian J Lepr 1996, 68 (3): 227-234.
9 NATIONS S. P, KATZ J. S., LYDE C. B. e BAROHN R. J. Leprous neuropathy: an American perspective. Semin Neurol 1998, 18 (1): 113-124.
10 OO1 W. W. e MOSCHELLA S. L. Update on leprosy in immigrants in the United States: status in the year 2000. Clin Infect Dis 2001, 32 (6): 930-937.
11 PEARSON J. M. H. The evaluation of nerve damage in leprosy. Lepr Rev 1982, 53: 119-130.
12 PIMENTEL M. I. F. Neurites na hansenfase: significado de parâmetros clínicos e epidemiológicos na indução e agravamento das incapacidades físicas em pacientes multibacilares. Tese de Doutorado. Universidade Federal do Rio de Janeiro. Rio de Janeiro, Novembro de 1998, 99 p.
13 PONNIGHAUS I. M., BOERRIGTER G., FINE P. E. M, PONNIGHAUS J. M. e RUSSELL J. Disabilities in leprosy patients ascertained in a total population survey in Karonga District, Northern Malawi. Lepr Rev 1990, 61:366-374.
14 RAO P S., SUBRAMANIAN M. e SUBRAMANIAN G. Deformity incidence in leprosy patients treated with multidrug therapy. Indian J Lepr 1994, 66 (4): 449-415.
15 REDDY B. N. e BANSAL R. D. An epidemiological study of leprosy disability in a leprosy endemic rural population of Pondicherry (South India). Indian J Lepr 1984, 56 (2): 191-199.
16 RICHARDUS J. H., FINLAY K. M., CROFT R. P. e SMITH W. C. S. Nerve function impairment in leprosy at diagnosis and at completion of MDT a retrospective cohort study of 786 patients in Bangladesh. Lepr Rev 1996, 67: 297-305.
17 RICHARDUS J. H., MEIMA A, CROFT R. P. e HABBEMA J. D. Case detection, gender and disability in Bangladesh: a trend analysis. Lepr Rev 1999, 70 (2): 160-173.
18 RIDLEY D. S. e JOPLING W. H. Classification of leproy according to immunity. A five-group system. Int. Lepr 1966, 34 (3): 255-272.
19 ROBERTSON L. M., NICHOLLS P. G. e BUTLIN R. Delay in presentation and start of treatment in leprosy: experience in an out-patient clinic in Nepal. Lepr Rev 2000, 71 (4): 511-516.
20 SADEGHI P, DUPREE M. e CARLSON J A Delay in diagnosis: indeterminate leprosy presenting with rheumatic manifestations. J Cutan Med Surg 2000, 4 (1): 26-29.
21 SAUNDERSON P. The epidemiology of reactions and nerve damage. Lepr Rev 2000, 71 (Suppl): 5106-S110.
22 SCHIPPER A, LUBBERS W. J. HOGEWEG M. e DE SOLDENHOFF R. Disabilities of hands, feet and eyes in newly diagnosed leprosy patients in eastern Nepal. Lepr Rev 1994, 65 (3): 239-247.
23 SMITH W. C. S., ANTIN U. S. e PATOLE A R. Disability in leprosy: a relevant measurement of progress in leprosy control. Lepr Rev 1980, 51: 155-166.
24 SRINIVASAN H. Newer tasks for leprosy workers. Indian J Lepr 1990, 62 (4): 409-415.
25 SRINIVASAN H. Not by chemotherapy alone. Indian J Lepr 1994, 66 (2): 209-221.
26 WITTENHORST B., VREE M. L., TEN HAM P. B. e VELEMA J. P. The National Leprosy Control Programme of Zimbabwe: a data analysis, 1983 —1992. Lepr Rev 1998, 69 (1): 46 — 56.
27 WU X. S., NING Y., SHI L. e YANG J. W. An epidemiological analysis of leprosy from 1951 —1996 in Sichuan. Indian J Lepr 2000, 72 (2): 215- 226.